Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@article{Young2009AsymmetricDA,
  title={Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.},
  author={Jill Melendez Young and Norma C Terrin and Xuelei Wang and Tom Greene and Gerald J. Beck and John Walter Kusek and Allan J. Collins and Mark J Sarnak and Vandana Menon},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2009},
  volume={4 6},
  pages={1115-20}
}
BACKGROUND AND OBJECTIVES Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. DESIGN, SETTINGS, PARTICIPANTS, & METHODS The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…